Apellis Pharmaceuticals (Apellis Pharmaceuticals) Total Inventories : $161.3 Mil (As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Apellis Pharmaceuticals Total Inventories?

Apellis Pharmaceuticals's total inventories for the quarter that ended in Mar. 2024 was $161.3 Mil. Apellis Pharmaceuticals's average total inventories from the quarter that ended in Dec. 2023 to the quarter that ended in Mar. 2024 was $153.8 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Apellis Pharmaceuticals's Net-Net Working Capital per share for the quarter that ended in Mar. 2024 was $0.35.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Apellis Pharmaceuticals's Days Inventory for the three months ended in Mar. 2024 was 694.56.

Inventory Turnover measures how fast the company turns over its inventory within a year. Apellis Pharmaceuticals's Inventory Turnover for the quarter that ended in Mar. 2024 was 0.13.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Apellis Pharmaceuticals's Inventory-to-Revenue for the quarter that ended in Mar. 2024 was 0.89.

Apellis Pharmaceuticals Total Inventories Historical Data

The historical data trend for Apellis Pharmaceuticals's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apellis Pharmaceuticals Total Inventories Chart

Apellis Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Inventories

Get a 7-Day Free Trial

16.29

85.71

146.36

Apellis Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Inventories	Get a 7-Day Free Trial															85.48	103.22	98.55	146.36	161.28

Apellis Pharmaceuticals Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

Apellis Pharmaceuticals (NAS:APLS) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Apellis Pharmaceuticals's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2024 is

	Net-Net Working Capital Per Share (Q: Mar. 2024 )
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(325.923	+	0.75 * 267.837	+	0.5 * 161.283	-	565.254
-	0	-	0)	/	121.264
=	0.35

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Apellis Pharmaceuticals's Days Inventory for the three months ended in Mar. 2024 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Mar. 2024 )	/	Cost of Goods Sold (Q: Mar. 2024 )	*	Days in Period
	=	153.8225	/	20.209	*	365 / 4
	=	694.56

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Apellis Pharmaceuticals's Inventory Turnover for the quarter that ended in Mar. 2024 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Mar. 2024 )	/	Average Total Inventories (Q: Mar. 2024 )
	=	20.209	/	153.8225
	=	0.13

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Apellis Pharmaceuticals's Inventory to Revenue for the quarter that ended in Mar. 2024 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	153.8225	/	172.325
	=	0.89

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

Apellis Pharmaceuticals Total Inventories Related Terms

Thank you for viewing the detailed overview of Apellis Pharmaceuticals's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.

Apellis Pharmaceuticals (Apellis Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Apellis Pharmaceuticals Inc (NAS:APLS) » Definitions » Total Inventories

Comparable Companies

Traded in Other Exchanges

1JK:Germany

Address

100 Fifth Avenue, Waltham, MA, USA, 02451

Website

https://www.apellis.com

Apellis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3 the central protein in the complement cascade.

Executives

Karen Lewis	officer: Chief People Officer	APELLIS PHARMACEUTICALS, INC., 100 5TH AVENUE, 3RD FLOOR, WALTHAM MA 02451
Mark Jeffrey Delong	officer: Senior Vice President	100 5TH AVENUE, 3RD FLOOR, WALTHAM MA 02451
James George Chopas	officer: See Remarks	950 WINTER STREET, WALTHAM MA 02451
Adam J. Townsend	officer: See Remarks	C/O APELLIS PHARMACEUTICALS, INC., 6400 WESTWIND WAY, SUITE A, CRESTWOOD KY 40014
David O. Watson	officer: General Counsel	6400 WESTWIND WAY, SUITE A, CRESTWOOD KY 40014
Pascal Deschatelets	officer: Chief Operating Officer	6400 WESTWIND WAY, SUITE A, CRESTWOOD KY 40014
Jeffrey Eisele	officer: See Remarks	APELLIS PHARMACEUTICALS, INC., 100 5TH AVENUE, 3RD FLOOR, WALTHAM MA 02451
Nur Nicholson	officer: Chief Technical Officer	APELLIS PHARMACEUTICALS, INC., 100 5TH AVENUE, 3RD FLOOR, WALTHAM MA 02451
Timothy Eugene Sullivan	officer: Chief Financial Officer	800 BOYLSTON ST., SUITE 3310, PRUDENTIAL TOWER C/O AJU IB INVESTMENT, BOSTON MA 02199
Cedric Francois	director, 10 percent owner, officer: Chief Executive Officer	6400 WESTWIND WAY, SUITE A, CRESTWOOD KY 40014
Caroline Baumal	officer: Chief Medical Officer	C/O APELLIS PHARMACEUTICALS, INC., 100 5TH AVENUE, 3RD FLOOR, WALTHAM MA 02451
A. Sinclair Dunlop	director	C/O APELLIS PHARMACEUTICALS, INC., 6400 WESTWIND WAY, SUITE A, CRESTWOOD KY 40014
Lukas Scheibler	officer: See Remarks	C/O APELLIS PHARMACEUTICALS, INC., 6400 WESTWIND WAY, SUITE A, CRESTWOOD KY 40014
Alec Machiels	director	505 PARK AVENUE, 21ST FLOOR, NEW YORK NY 10022
Federico Grossi	officer: See Remarks	C/O APELLIS PHARMACEUTICALS, INC., 6400 WESTWIND WAY, SUITE A, CRESTWOOD KY 40014